Zachary Hunter
Pre-Doctoral Trainee
Boston University School of Medicine, Division of Graduate Medical Sciences
Dept of Pathology & Laboratory Medicine

Waldenström's macroglobulinemia
Whole Genome Sequencing
Lymphoma Predisposition
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Vos JM, Tsakmaklis N, Patterson CJ, Meid K, Castillo JJ, Brodsky P, Ganz T, Pals ST, Kersten MJ, Xu L, Yang G, Treon SP, Hunter ZR. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica. 2017 Nov; 102(11):e452-e455. PMID: 28798070.
  2. Castillo JJ, Hunter ZR, Yang G, Treon SP. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. Expert Rev Hematol. 2017 Aug; 10(8):739-744. PMID: 28617062.
  3. Gustine JN, Meid K, Dubeau T, Hunter ZR, Xu L, Yang G, Ghobrial IM, Treon SP, Castillo JJ. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 Jun; 177(5):717-725. PMID: 28485115.
  4. Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo JJ, Furman RR, Hunter ZR, Treon SP. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017 May 04; 129(18):2519-2525. PMID: 28235842; DOI: 10.1182/blood-2017-01-761726;.
  5. Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. J Clin Oncol. 2017 Feb 13; JCO2016710814. PMID: 28294689; DOI: 10.1200/JCO.2016.71.0814;.
  6. Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunter ZR, Yang G, Patterson CJ, Gustine J, Castillo JJ, Matous J, Ghobrial IM. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404. PMID: 27836860; DOI: 10.1158/1078-0432.CCR-16-1918;.
  7. Gustine JN, Meid K, Hunter ZR, Xu L, Treon SP, Castillo JJ. MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. Br J Haematol. 2016 Oct 17. PMID: 27748515; DOI: 10.1111/bjh.14386;.
  8. Castillo JJ, Hunter ZR, Yang G, Argyropoulos K, Palomba ML, Treon SP. Future therapeutic options for patients with Waldenström macroglobulinemia. Best Pract Res Clin Haematol. 2016 Jun; 29(2):206-215. PMID: 27825467; DOI: 10.1016/j.beha.2016.08.021;.
  9. Castillo JJ, Gustine JN, Meid K, Dubeau T, Yang G, Xu L, Hunter ZR, Treon SP. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 Apr; 58(4):1002-1004. PMID: 27562445; DOI: 10.1080/10428194.2016.1222380;.
  10. Vos JM, Gustine J, Rennke HG, Hunter Z, Manning RJ, Dubeau TE, Meid K, Minnema MC, Kersten MJ, Treon SP, Castillo JJ. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630. PMID: 27468978; DOI: 10.1111/bjh.14279;.
Showing 10 of 70 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 70 publications over 13 distinct years, with a maximum of 10 publications in 2011

Contact for Mentoring:

Hunter's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department